Seastar Medical Holding vs Insight Molecular Diagnostics
Insight Molecular Diagnostics is the larger business, with $4.1m of revenue in fiscal 2025 against $1.2m for Seastar Medical Holding (3.3 times as much). Seastar Medical Holding grew faster (814.1% against 115.6%). Seastar Medical Holding kept more of each dollar of sales as profit: a net margin of -984.6% against -1238.5%.
| Latest fiscal year | Seastar Medical HoldingICU, 2025 | Insight Molecular DiagnosticsIMDX, 2025 |
|---|---|---|
| Revenue | $1.2m | $4.1m |
| Revenue growth | 814.1% | 115.6% |
| Net income | −$12.2m | −$50.2m |
| Operating margin | -986.6% | — |
| Net margin | -984.6% | -1238.5% |
| Return on equity | — | — |
| Free cash flow | — | −$25.4m |
| Cash | — | $11.6m |
| Total debt | $525,000 | $0 |
| Debt to equity | 5.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 17 | — |
| Market value | $8.3m | $91.3m |
| Price vs our value range | — | — |
| Moat score | — | 20 (Weak) |
| Insider trades, 12 months | 3 buys, 0 sales | 14 buys, 0 sales |